Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Mol Biol (Mosk) ; 56(3): 503-509, 2022.
Artigo em Russo | MEDLINE | ID: mdl-35621107

RESUMO

Coronaviridae is a family of single-stranded RNA (ssRNA) viruses that can cause diseases with high mortality rates. SARS-CoV-1 and MERS-CoV appeared in 2002-2003 and 2012, respectively. A novel coronavirus, SARS-CoV-2, emerged in 2019 in Wuhan (China) and has caused more than 5 million deaths in worldwide. The entry of SARS-CoV-1 into the cell is due to the interaction of the viral spike (S) protein and the cell protein, angiotensin-converting enzyme 2 (ACE2). After infection, virus assembly occurs in Golgi apparatus-derived vesicles during exocytosis. One of the possible participants in this process is LAMP1 protein. We established transgenic Vero cell lines with increased expression of human LAMP1 gene and evaluated SARS-CoV-1 and SARS-CoV-2 production. An increase in the production of both viruses in LAMP1-expressing cells when compared with Vero cells was observed, especially in the presence of trypsin during infection. From these results it can be assumed that LAMP1 promotes SARS-CoV-1 and SARS-CoV-2 production due to enhanced exocytosis.


Assuntos
COVID-19 , SARS-CoV-2 , Animais , Animais Geneticamente Modificados , COVID-19/genética , Chlorocebus aethiops , Humanos , Proteínas de Membrana Lisossomal , Peptidil Dipeptidase A/genética , SARS-CoV-2/genética , Células Vero
2.
Mol Biol ; 56(3): 463-468, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35693978

RESUMO

Coronaviridae is a family of single-stranded RNA (ssRNA) viruses that can cause diseases with high mortality rates. SARS-CoV-1 and MERS-CoV appeared in 2002‒2003 and 2012, respectively. A novel coronavirus, SARS-CoV-2, emerged in 2019 in Wuhan (China) and has caused more than 5 million deaths in worldwide. The entry of SARS-CoV-1 into the cell is due to the interaction of the viral spike (S) protein and the cell protein, angiotensin-converting enzyme 2 (ACE2). After infection, virus assembly occurs in Golgi apparatus-derived vesicles during exocytosis. One of the possible participants in this process is LAMP1 protein. We established transgenic Vero cell lines with increased expression of human LAMP1 gene and evaluated SARS-CoV-1 and SARS-CoV-2 production. An increase in the production of both viruses in LAMP1-expressing cells when compared with Vero cells was observed, especially in the presence of trypsin during infection. From these results it can be assumed that LAMP1 promotes SARS-CoV-1 and SARS-CoV-2 production due to enhanced exocytosis.

4.
Farmakol Toksikol ; 49(6): 58-61, 1986.
Artigo em Russo | MEDLINE | ID: mdl-3817148

RESUMO

Furfuryl amine salt of 4-chloro-N-(2-furylmethyl)-5-sulfamoyl anthranilic acid was shown to exert more pronounced diuretic and saluretic action in rats, mice and dogs than that of furosemide. The previous administration of furfuryl amine salt of furosemide promoted normalization of the excretory processes of the kidney and increased survival rate of rats in ischemia of the single kidney. The antiedema activity of the drug was found to be much more pronounced than that of furosemide.


Assuntos
Diuréticos/farmacologia , Sulfanilamidas/farmacologia , ortoaminobenzoatos/farmacologia , Injúria Renal Aguda/etiologia , Injúria Renal Aguda/prevenção & controle , Animais , Diurese/efeitos dos fármacos , Diuréticos/uso terapêutico , Cães , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Edema/tratamento farmacológico , Feminino , Furosemida/farmacologia , Isquemia/complicações , Isquemia/tratamento farmacológico , Rim/irrigação sanguínea , Masculino , Camundongos , Natriurese/efeitos dos fármacos , Ratos , Sulfanilamidas/uso terapêutico , ortoaminobenzoatos/uso terapêutico
5.
Farmakol Toksikol ; 49(4): 46-9, 1986.
Artigo em Russo | MEDLINE | ID: mdl-3758328

RESUMO

Experiments on mice, rats and dogs showed that furosemide manufactured in the USSR is not inferior by its specific activity to furosemide manufactured abroad. Furosemide manufactured in the USSR and furosemide-substance made in Finland were compared at three doses--1, 5 and 25 mg/kg. The bioavailability of furosemide tablets manufactured in the USSR and that of "Polfa" production tablets studied on rats (5 and 25 mg/kg) and dogs (40 mg) appeared to be identical.


Assuntos
Furosemida/farmacologia , Animais , Disponibilidade Biológica , Diurese/efeitos dos fármacos , Cães , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Finlândia , Furosemida/metabolismo , Camundongos , Natriurese/efeitos dos fármacos , Polônia , Ratos , Comprimidos , U.R.S.S.
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA